BioLife Solutions, Inc.
BioLife Solutions (BLFS) provides specialised biopreservation media, storage systems and cold-chain logistics tools used by developers and manufacturers of cell and gene therapies. With a market capitalisation of about $1.33bn, the company sits at the intersection of life-science tools and advanced therapeutics supply chains. Investors should note it earns revenue largely from consumables and distribution services, which can support recurring sales, but growth depends on the pace of adoption of cell and gene therapies and on partners’ clinical and commercial progress. There is exposure to regulatory approvals, competitive products, and the capital intensity of scaling biological supply chains. Financial performance can be variable as customers move through development cycles. This note is for educational purposes only and not personalised advice; investors should assess whether a growth-oriented, higher‑risk healthcare stock fits their objectives and consider seeking independent financial advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BioLife Solutions' stock with a target price of $27.11, indicating growth potential.
Financial Health
BioLife Solutions is generating solid revenue and cash flow, but its profitability is modest.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BLFS
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore Basket3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Cell therapy demand
Rising development of cell and gene therapies can boost recurring consumable sales, though adoption rates and customer progress vary and affect revenue.
Cold‑chain logistics
Reliable temperature‑controlled transport is essential for biologics; operational execution and regulation matter, and lapses can affect customers and revenues.
Early‑stage volatility
The company sits in a growth phase with potential upside, but financial results can be lumpy and sensitive to partner timelines and broader biotech cycles.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
